Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease Treatment
| Primer Autor |
Olloquequi, Jordi
|
| Co-autores |
Ettcheto, Miren
Cano, Amanda
Fortuna, Ana
Bicker, Joana
Sanchez-Lopez, Elena
Paz, Cristian
Urena, Jesus
Verdaguer, Ester
Auladell, Carme
Camins, Antoni
|
| Título |
Licochalcone A: A Potential Multitarget Drug for Alzheimer's Disease Treatment
|
| Editorial |
MDPI
|
| Revista |
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
|
| Lenguaje |
en
|
| Resumen |
Licochalcone A (Lico-A) is a flavonoid compound derived from the root of the Glycyrrhiza species, a plant commonly used in traditional Chinese medicine. While the Glycyrrhiza species has shown promise in treating various diseases such as cancer, obesity, and skin diseases due to its active compounds, the investigation of Licochalcone A's effects on the central nervous system and its potential application in Alzheimer's disease (AD) treatment have garnered significant interest. Studies have reported the neuroprotective effects of Lico-A, suggesting its potential as a multitarget compound. Lico-A acts as a PTP1B inhibitor, enhancing cognitive activity through the BDNF-TrkB pathway and exhibiting inhibitory effects on microglia activation, which enables mitigation of neuroinflammation. Moreover, Lico-A inhibits c-Jun N-terminal kinase 1, a key enzyme involved in tau phosphorylation, and modulates the brain insulin receptor, which plays a role in cognitive processes. Lico-A also acts as an acetylcholinesterase inhibitor, leading to increased levels of the neurotransmitter acetylcholine (Ach) in the brain. This mechanism enhances cognitive capacity in individuals with AD. Finally, Lico-A has shown the ability to reduce amyloid plaques, a hallmark of AD, and exhibits antioxidant properties by activating the nuclear factor erythroid 2-related factor 2 (Nrf2), a key regulator of antioxidant defense mechanisms. In the present review, we discuss the available findings analyzing the potential of Lico-A as a neuroprotective agent. Continued research on Lico-A holds promise for the development of novel treatments for cognitive disorders and neurodegenerative diseases, including AD. Further investigations into its multitarget action and elucidation of underlying mechanisms will contribute to our understanding of its therapeutic potential.
|
| Fecha Publicación |
2023
|
| Tipo de Recurso |
artículo de revisión
|
| doi |
10.3390/ijms241814177
|
| Formato Recurso |
PDF
|
| Palabras Claves |
neurodegeneration
cognitive enhancement
multi-target therapy
|
| Ubicación del archivo | |
| Categoría OCDE |
Bioquímica y biología molecular
Química
|
| Materias |
neurodegeneración
mejora cognitiva
terapia multiobjetivo
|
| Identificador del recurso (Mandatado-único) |
artículo de revisión
|
| Versión del recurso (Recomendado-único) |
versión publicada
|
| License |
CC BY 4.0
|
| Condición de la licencia (Recomendado-repetible) |
CC BY 4.0
|
| Derechos de acceso |
acceso abierto
|
| Access Rights |
acceso abierto
|
| Id de Web of Science |
WOS:001073766300001
|
| ISSN |
1661-6596
|
| Tipo de ruta |
verde# dorado
|
| Categoría WOS |
Bioquímica y biología molecular
Química
|
| Referencia del Financiador (Mandatado si es aplicable-repetible) |
MICINN PID2021-123462OB-I00
MICINN PID2021-122473OA-I00
GENCAT 2021 SGR 00288
CIBERNED CB06/05/2004 PI2021/03
FCT 127303
ISCIII CD22/00125
ADEY
INUB CEX2021-001159-M
|
cienciaabierta.ufro.cl
ciencia.abierta@ufrontera.cl